MPN | Tumor | CURE
Key claim: The FDA has accepted a supplemental application for ropeginterferon alfa-2b (Besremi) in ET, granted orphan drug designation to CK0804 cell therapy for myelofibrosis, and granted breakthrough therapy designation to INCA033989 for essential thrombocythemia.
Abstract
The FDA has accepted a supplemental application for Besremi in adults with essential thrombocythemia with an August 30, 2026 action date. The FDA granted orphan drug designation to CK0804, an investigational cell therapy being studied for patients with myelofibrosis. The FDA granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.
Why this matters
Three FDA regulatory actions in a single update span ET (Besremi sNDA; INCA033989 breakthrough designation) and MF (CK0804 orphan designation), signaling parallel maturation of distinct therapeutic classes — pegylated interferon, mutant-CALR-directed antibody, and allogeneic Treg cell therapy — across MPN subtypes. The INCA033989 designation is particularly notable for bridging the CALR-mutated ET and MF populations under a shared neoepitope-targeting strategy, while CK0804 introduces cell therapy into the MF landscape. Together they reflect accelerating regulatory momentum for subtype-specific and genotype-stratified MPN therapeutics.